[{"id":"4bfdbfd4-3bf6-4959-a48c-30dc58c15c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05575804","created_at":"2022-10-12T13:56:41.863Z","updated_at":"2024-07-02T16:35:17.616Z","phase":"Phase 1/2","brief_title":"GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT05575804","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Irene (pyrotinib) • GQ1001"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-26"},{"id":"6a6417f1-7a1c-4f5d-b375-14a617d5a686","acronym":"","url":"https://clinicaltrials.gov/study/NCT04450732","created_at":"2021-01-18T21:24:44.908Z","updated_at":"2024-07-02T16:35:27.134Z","phase":"Phase 1","brief_title":"Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04450732","lead_sponsor":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GQ1001"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 07/07/2020","start_date":" 07/07/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-12-05"}]